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PP-103 Horizontal transmission of hepatitis B (HB)
among non-immune paediatric patients at the
National Cancer Institute of Sri Lanka (NCISL)
C.G.U.A. Patabendige1 *, A. Pinnaduwa1, C. Hallala1.
1National Cancer Institute of Sri Lanka, Sri Lanka
Objectives:
• To determine seroconversion rate of immuno-
compromised children following HB vaccination.
• To determine seroconversion rate of mothers/guardians
following vaccination.
• To determine percentage of non-immune children
developing HB when on close contact.
Methods: A prospective descriptive study was carried out
for two years from January 2007. Blood collected from
all new children (113 in 2007 and 208 in 2008) and
guardians (109 in 2007 and 279 in 2008) on admission
were tested for HBsAg. HBs Negative candidates were given
full course of vaccination. HBs antibodies were checked
06 weeks after the last dose. Positive candidates are
immune and if negative HB vaccination was repeated. If
HBs antibodies are still negative, they are non-responders.
If one develops clinical evidence of HB infection while
undergoing vaccination, they were checked for HBsAg to
detect infection.
Results: Rate of seroconversion in children after ﬁrst course
of vaccination in 2007 is 64.60% while that for 2008 is
87.01%. Following two courses of vaccination in children
seroconversion rates are higher which are 92.92% and
94.23% respectively. In guardians, after the ﬁrst course,
seroconversion rates are 76.14% and 85.66% respectively.
Following the two courses, the rates of seroconversion
of guardians are very high with 97.24% and 98.20% for
2007 and 2008 respectively. There are 20 non-responders
among children and 08 among guardians. Percentage of
children who are non-responders developing disease is
higher compared to the percentage of children developing
HB while on vaccination. None of the children who became
immune following HB vaccination developed hepatitis B
infection.
Conclusion: Contact isolation of hepatitis B infected
children is essential to prevent horizontal transmission
through close contact to immuno-compromised children who
are non responders and also to children during vaccination.
Continuation of existing policy for HB vaccination is
needed.
PP-104 An evaluation on quality of life in patients with
liver cirrhosis after S-adenosylmethionine
(SAM-e) therapy
J. Liu1 *, L. Peng1. 1The Third Afﬁliated Hospital of Sun
Yat-sen University, China
Background: To explore the quality of life (QOL) for HBV-
related liver cirrhosis (LC) patients. And the effect of SAM-e
therapy on QOL in patients with LC was evaluated.
Methods: A study based on 60 patients with LC (group A,
before SAM-e therapy, T0) and 60 healthy persons (group B)
was carried out using SF-36 questionnaire, and QOL were
compared between these two groups. After being given
SAM-e injection (1.0/d) therapy of two weeks (T1), group A
were given SAM-e tablets (1.0/d) therapy of two weeks (T2),
subsequently. At the same time 60 patients with LC without
SAM-e therapy (group C) were investigated. QOL were
compared using SF-36 questionnaire on T0, T1 and T2.
Results: Compared with group B, group A had lower QOL on
all scales and total scores (P < 0.05) of the SF-36 except for
PF and MH. On T1/T2 group B had higher QOL on GH, RP,
RE, VT, MH and total scores than before (P < 0.05). On T2
group B had higher QOL on GH, RP, RE and total scores than
that on T1 (P < 0.05).
Conclusion: QOL of patients with LC is more impaired than
healthy persons. SAM-e therapy will improve the QOL, and
the improvement will be strengthened with SAM-e tablets
therapy after the injection therapy.
PP-105 Screening of the target genes transactivated by
PS1TP2 protein with suppression subtractive
hybridization technique
J.-L. Chen1 *, J. Guo1, J. Cheng1. 1Beijing Ditan Hospital,
Capital Medical University, Beijing 100015, China
Background: PS1TP2 is one of genes transactivated by
pre-S1. Its function is unknown. To get insight into the
transactivation mechanism of PS1TP2 protein, the SSH was
used for identiﬁcation of transactivating relative target
genes of PS1TP2 protein.
Methods Suppression subtractive hybridization technique
and bioinformatics technique were used, the mRNA from
HepG2 cells transfected with pcDNA3.1( )-PS1TP2 and
pcDNA3.1( ) empty vector was isolated, respectively; cDNA
was synthesized. After digestion with restriction enzyme
RsaI, cDNA fragments were obtained. Tester cDNA was
then divided into two groups and ligated to the speciﬁc
adaptor 1 and adaptor 2, respectively. After tester cDNAwas
hybridized with driver cDNA twice and underwent two times
of nested PCR, ampliﬁed cDNA fragments were subcloned
into pGEM-Teasy vectors to set up the subtractive library.
Ampliﬁcation of the library was carried out with E. coli strain
DH5a. The cDNA was sequenced and analyzed in GenBank
with Blast search after PCR.
Results: The subtractive library of genes transactivated by
PS1TP2 was constructed successfully (Table 1).
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